Teriflunomide (Aubagio) Effects on Cognitive and Vocational Outcomes, as Related to Neurodegeneration in Multiple Sclerosis: A Prospective, Observational, Single-blinded Study
Latest Information Update: 18 Mar 2021
At a glance
- Drugs Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 18 Mar 2021 Status changed from active, no longer recruiting to completed.
- 14 Nov 2018 Planned End Date changed from 5 Aug 2019 to 30 Nov 2020.
- 14 Nov 2018 Planned primary completion date changed from 1 Aug 2018 to 15 Nov 2020.